Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age - 09/08/11
on behalf of a Cutivate Lotion Study Group
San Diego, California, and Portland, Oregon
Abstract |
A novel lotion formulation of fluticasone propionate 0.05% has recently become available. Two large, randomized, placebo-controlled, double-blind studies involving 438 subjects demonstrated its efficacy and safety when applied once daily in the treatment of atopic dermatitis in subjects from 3 months to 87 years of age. The studies were limited to 4 weeks duration of use of fluticasone lotion and did not assess longer term efficacy or side effects.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| The study was sponsored by GlaxoSmithKline, NJ, USA. Cutivate is a trademark of the GSK group of companies. Funding sources: None. Conflicts of interest: None identified. |
Vol 54 - N° 4
P. 715-717 - aprile 2006 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
